- Home
- ROOT vs ARQT Comparison
ROOT vs ARQT Comparison
Compare ROOT & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- ARQT
- Stock Information
- Founded
- ROOT 2015
- ARQT 2016
- Country
- ROOT United States
- ARQT United States
- Employees
- ROOT N/A
- ARQT N/A
- Industry
- ROOT Property-Casualty Insurers
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- ARQT Health Care
- Exchange
- ROOT Nasdaq
- ARQT Nasdaq
- Market Cap
- ROOT 1.1B
- ARQT 1.1B
- IPO Year
- ROOT 2020
- ARQT 2020
- Fundamental
- Price
- ROOT $84.81
- ARQT $13.28
- Analyst Decision
- ROOT Buy
- ARQT Strong Buy
- Analyst Count
- ROOT 9
- ARQT 5
- Target Price
- ROOT $58.38
- ARQT $17.00
- AVG Volume (30 Days)
- ROOT 306.5K
- ARQT 2.2M
- Earning Date
- ROOT 02-19-2025
- ARQT 02-25-2025
- Dividend Yield
- ROOT N/A
- ARQT N/A
- EPS Growth
- ROOT N/A
- ARQT N/A
- EPS
- ROOT N/A
- ARQT N/A
- Revenue
- ROOT $1,044,599,999.00
- ARQT $138,708,000.00
- Revenue This Year
- ROOT N/A
- ARQT $209.03
- Revenue Next Year
- ROOT $8.55
- ARQT $49.00
- P/E Ratio
- ROOT N/A
- ARQT N/A
- Revenue Growth
- ROOT 215.11
- ARQT 182.84
- 52 Week Low
- ROOT $7.22
- ARQT $3.11
- 52 Week High
- ROOT $118.15
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- ROOT 60.96
- ARQT 46.96
- Support Level
- ROOT $71.75
- ARQT $13.79
- Resistance Level
- ROOT $81.34
- ARQT $16.20
- Average True Range (ATR)
- ROOT 5.32
- ARQT 0.95
- MACD
- ROOT 1.14
- ARQT -0.26
- Stochastic Oscillator
- ROOT 79.81
- ARQT 5.81
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.